| 2018 | | Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects | 김순선, 김진홍, 양민재, 임선교, 정재연, 조성원, 조효정 |
| 2017 | | Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma | 김순선, 김진우, 노충균, 신성재, 양민재, 원제환, 이기명, 정재연, 조성원, 조효정, 지재훈 |
| 2018 | | Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma | 김보현, 김순선, 김재근, 김진우, 김현지, 원제환, 이제희, 정재연, 조성원, 조효정 |
| 2017 | | Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Using 4-Hour Post-Endoscopic Retrograde Cholangiopancreatography Serum Amylase and Lipase Levels | 김순선, 김진홍, 노충균, 양민재, 유병무, 임선교, 조효정, 황재철 |
| 2014 | | Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. | 김순선, 안선주, 우현구, 정재연, 조성원, 조효정 |
| 2021 | | Prognostic value of alpha-fetoprotein in patients who achieve a complete response to transarterial chemoembolization for hepatocellular carcinoma | 김순선, 정재연, 조효정 |
| 2017 | | Response to Dr Giannini et al | 김순선, 정재연, 조성원, 조효정 |
| 2013 | | Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B | 조효정 |
| 2014 | | Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B | 김순선, 김영배, 박주한, 안선주, 정재연, 조성원, 조효정 |
| 2021 | | SPP1 biomarker for predicting the response of anticancer drugs to liver cancer and use thereof | 김순선, 은정우, 정재연, 조효정 |
| 2015 | | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. | 김순선, 신성재, 유병무, 정재연, 조성원, 조효정 |
| 2020 | | Use for detection of hepatocellular carcinoma specific MLH1 circulating tumor DNA mutation | 김순선, 은정우, 정재연, 조효정 |
